Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Ibrutinib, an irreversible Bruton's tyrosine kinase (Btk) inhibitor, is effective for B-cell lymphoproliferative disorders.
• Ibrutinib use is associated with an increased risk of bleeding events, ranging from minor to life-threatening.
• Limited data exist on managing ibrutinib in high-bleeding-risk patients or those on antithrombotic therapy.

Purpose of the Study:

• To review the pathophysiology of ibrutinib-induced bleeding.
• To provide risk reduction strategies for clinical scenarios involving ibrutinib and bleeding risk.
• To discuss the implications of ibrutinib use on antithrombotic therapy and potential cardiovascular effects.

Main Methods:

• Literature review of studies on ibrutinib, bleeding events, platelet function, and anticoagulation.
• Analysis of clinical data and expert recommendations regarding ibrutinib management.
• Synthesis of information on drug interactions and risk mitigation strategies.

Main Results:

• Ibrutinib affects multiple platelet signaling pathways, contributing to its bleeding risk.
• Specific recommendations are provided for managing concomitant medications, including NSAIDs, aspirin, vitamin K antagonists, and direct oral anticoagulants.
• The potential cardiovascular protective effects of ibrutinib monotherapy remain largely unknown.

Conclusions:

• Clinicians must carefully consider bleeding risks and drug interactions when prescribing ibrutinib.
• Risk mitigation strategies are essential for patients on ibrutinib, particularly those requiring antithrombotic therapy.
• Further research is needed to clarify the cardiovascular effects of ibrutinib.